Therapeutics targeting tumor necrosis factor-α (TNF-α) and interleukin (IL) 1 and 6 are used to treat rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis. The gene discussed is TNF; the disease is inflammatory bowel disease.